Identifier
Created
Classification
Origin
09LJUBLJANA63
2009-03-10 16:08:00
UNCLASSIFIED//FOR OFFICIAL USE ONLY
Embassy Ljubljana
Cable title:
SLOVENIA: 2009 SPECIAL 301 REVIEW - ADDITIONAL INFO
how-toVZCZCXRO5377 PP RUEHAG RUEHDF RUEHIK RUEHLZ RUEHROV RUEHSR DE RUEHLJ #0063 0691608 ZNR UUUUU ZZH P 101608Z MAR 09 FM AMEMBASSY LJUBLJANA TO RUEHC/SECSTATE WASHDC PRIORITY 7209 INFO RUCNMEM/EU MEMBER STATES
UNCLAS LJUBLJANA 000063
SENSITIVE
SIPDIS
EEB/TPP/IPE - TMCGOWAN
DEPT PASS TO USTR (JCHOE-GROVES)
E.O. 12958: N/A
TAGS: ECON ETRD KIPR SI
SUBJECT: SLOVENIA: 2009 SPECIAL 301 REVIEW - ADDITIONAL INFO
REF: A. SECSTATE 8401
B. LUBLJANA 56
(SBU) The Slovenian Agency for Medicinal Products and Medical
Devices shared new information with EmbOffs that directly
addresses PhRMA's concerns, and reinforces Post's
recommendation that Slovenia not be included on the watchlist
(ref B). The PhRMA complaint alleges that "A new draft
pricing regulation was recently prepared, but has neither
been officially adopted by the Minister of Health (MoH),nor
published in the Official Gazette. The new pricing
regulation could pose a number of significant problems,
particularly with respect to a new proposal under
consideration to set the maximum Slovenian price as a
fraction of reference countries' prices as opposed to full
prices." However, on January 30, the government of Slovenia
adopted new pricing regulation, which was published in the
Official Gazette on January 31. The new pricing regulation
set the price at 100% of the reference countries' prices.
Therefore, PhRMA's concerns appear to have been fully
addressed and Slovenia should NOT be included on the Special
301 watchlist.
FREDEN
SENSITIVE
SIPDIS
EEB/TPP/IPE - TMCGOWAN
DEPT PASS TO USTR (JCHOE-GROVES)
E.O. 12958: N/A
TAGS: ECON ETRD KIPR SI
SUBJECT: SLOVENIA: 2009 SPECIAL 301 REVIEW - ADDITIONAL INFO
REF: A. SECSTATE 8401
B. LUBLJANA 56
(SBU) The Slovenian Agency for Medicinal Products and Medical
Devices shared new information with EmbOffs that directly
addresses PhRMA's concerns, and reinforces Post's
recommendation that Slovenia not be included on the watchlist
(ref B). The PhRMA complaint alleges that "A new draft
pricing regulation was recently prepared, but has neither
been officially adopted by the Minister of Health (MoH),nor
published in the Official Gazette. The new pricing
regulation could pose a number of significant problems,
particularly with respect to a new proposal under
consideration to set the maximum Slovenian price as a
fraction of reference countries' prices as opposed to full
prices." However, on January 30, the government of Slovenia
adopted new pricing regulation, which was published in the
Official Gazette on January 31. The new pricing regulation
set the price at 100% of the reference countries' prices.
Therefore, PhRMA's concerns appear to have been fully
addressed and Slovenia should NOT be included on the Special
301 watchlist.
FREDEN